Jasper Ridge Partners’s Keros Therapeutics KROS Stock Holding History

Jasper Ridge Partners’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,042	Closed	-$220K	–	150
2022 Q1	$220K	Hold	4,042	–	–	0.01%	142
2021 Q4	$236K	Sell	4,042 -41,431	-91%	-$2.07M	0.01%	143
2021 Q3	$1.8M	Hold	45,473	–	–	0.08%	83
2021 Q2	$1.93M	Buy	+45,473	New	+$2.46M	0.1%	77

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jasper Ridge Partners's KROS Position: Q2 2022 in Review

Jasper Ridge Partners sold out of Keros Therapeutics (KROS) in Q2 2022, closing a stake of 4,042 shares — an estimated $220K sold.

Jasper Ridge Partners first reported a position in KROS in Q2 2021 and held it in 4 quarters. The position peaked at $1.93M in Q2 2021. 104 funds tracked by Wall St. Rank hold KROS as of Q2 2022.

Jasper Ridge Partners reported no remaining Keros Therapeutics position as of Q2 2022 after selling out during the quarter.
Jasper Ridge Partners sold 4,042 Keros Therapeutics shares in Q2 2022, an estimated $220K.
Jasper Ridge Partners first reported a position in Keros Therapeutics in Q2 2021 and held it in 4 quarters.
Jasper Ridge Partners's Keros Therapeutics position peaked at $1.93M in Q2 2021.
104 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2022.

Based on Jasper Ridge Partners's 13F filing for Q2 2022, filed 15 Aug 2022.